title: Clinical characteristics and treatment outcome of pediatric patients with chronic myeloid leukemia.
abstract: As chronic myeloid leukemia is rare in children, most data on imatinib mesylate therapy is derived from adult studies. We retrospectively evaluated pediatric (<14 years) patients with Ph+ chronic myeloid leukemia treated with imatinib mesylate, from January 2003 through June 2008. Of the 12 chronic myeloid leukemia patients (2% of all leukemias) 11 were in chronic phase while one had myeloid blast crisis. Six subsequently underwent stem cell transplantation. Five patients had grade 3-4 arthralgia requiring therapy alteration. None achieved complete molecular remission (MR) with imatinib mesylate alone. In contrast 3/6 patients post stem cell transplantation have undetectable BCR-ABL. Three patients relapsed to chronic phase (1 imatinib mesylate; 2 stem cell transplantation). Relapse free survival is 65.6% at four years and all are alive. Imatinib mesylate is effective therapy for children with chronic myeloid leukemia. However, cure probably requires stem cell transplantation. Acute toxicity of imatinib mesylate is tolerable, but long-term effects on growing children are unknown. Pediatric patients with chronic myeloid leukemia should undergo stem cell transplantation when appropriate related donors are available.
authors.affiliation: Department of Pediatric Hematology/Oncology, King Faisal Specialist Hospital & Research Center, PO Box 3354, MBC 53 Riyadh 11211, Saudi Arabia. belgaumi@kfshrc.edu.sa
authors.forename: Asim F
authors.initials: AF
authors.lastname: Belgaumi
authors.forename: Ali
authors.initials: A
authors.lastname: Al-Shehri
authors.forename: Mouhab
authors.initials: M
authors.lastname: Ayas
authors.forename: Mohammed
authors.initials: M
authors.lastname: Al-Mahr
authors.forename: Amel
authors.initials: A
authors.lastname: Al-Seraihy
authors.forename: Ali
authors.initials: A
authors.lastname: Al-Ahmari
authors.forename: Hassan
authors.initials: H
authors.lastname: El-Solh
mesh_terms: D001549:Benzamides; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000401:mortality / Q000628:therapy*; D008297:Male; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate
references.citation: N Engl J Med. 2006 Dec 7;355(23):2408-17
references.pmid: 17151364
references.citation: Pediatr Blood Cancer. 2009 Dec;53(6):992-5
references.pmid: 19621426
references.citation: Leuk Res. 2002 Feb;26(2):129-41
references.pmid: 11755463
references.citation: Blood. 2007 Jun 1;109(11):4686-92
references.pmid: 17317858
references.citation: Bone Marrow Transplant. 2008 Oct;42 Suppl 2:S40-6
references.pmid: 18978743
references.citation: Leuk Res. 2009 Jul;33(7):871-5
references.pmid: 19307018
references.citation: Blood. 2004 Nov 1;104(9):2655-60
references.pmid: 15231574
references.citation: Blood. 2008 Feb 1;111(3):1039-43
references.pmid: 17932248
references.citation: Bone Marrow Transplant. 2003 Sep;32(5):459-69
references.pmid: 12942091
references.citation: J Clin Invest. 2000 Jan;105(1):3-7
references.pmid: 10619854
references.citation: Eur J Cancer. 2002 Sep;38 Suppl 5:S83-7
references.pmid: 12528778
references.citation: Nature. 2005 Jun 30;435(7046):1267-70
references.pmid: 15988530
references.citation: Leukemia. 2006 Feb;20(2):187-92
references.pmid: 16341042
references.citation: Blood. 2008 Apr 15;111(8):4022-8
references.pmid: 18256322
references.citation: Blood. 2007 Oct 15;110(8):2828-37
references.pmid: 17626839
references.citation: Clin Cancer Res. 2006 Aug 15;12(16):4899-907
references.pmid: 16914578
references.citation: N Engl J Med. 2003 Mar 13;348(11):994-1004
references.pmid: 12637609